More and more we can hear the world "POCT" in the diagnostic settings of microbiology! The POCT era in microbiology is coming and the main question is: which company is going to address the clinical needs correctly. The focus on the clinical needs is driving the products to be broth in identification (ID) delivery, the multiplex approaches are more and more loaded with the ID targets hopefully with the LLOD that is going to address clinical sensitivity that is needed for certain syndromic approaches. Why do we need broad multiplexing? Who needs all the results? Are they going to influence our escalation or de-escalation strategy in antibiotics proscribing?